Spinal Cord Stimulators: An Analysis of the Adverse Events Reported to the Australian Therapeutic Goods Administration

Background Spinal cord stimulators are used to treat intractable pain. Placebo-controlled trials of spinal cord stimulators typically involve short-term treatment and follow-up, so long-term safety and efficacy are unclear. Aim The aim of the study was to describe the adverse events relating to spinal cord stimulators reported to the Therapeutic Goods Administration of Australia between July 2012 and January 2019. Methods Adverse events were coded by seriousness, severity, body system affected, type of event, action taken, and attribution of fault. Data on the number of stimulators implanted and removed were sourced from the Admitted Patient Care Minimum Data Set. Results Five hundred twenty adverse events were reported for spinal cord stimulators. Most events were rated as severe (79%) or life-threatening (13%). Device malfunction was the most common event (56.5%). The most common action taken in response to an adverse event was surgical intervention with or without antibiotics (80%). The ratio of removals to implants was 4 per every 10 implanted. Conclusions Spinal cords stimulators have the potential for serious harm, and each year in Australia, many are removed. In view of the low certainty evidence of their long-term safety and effectiveness, our results raise questions about their role in providing long-term management of intractable pain.

[1]  K. Chakravarthy,et al.  Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation , 2020, Neuromodulation : journal of the International Neuromodulation Society.

[2]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[3]  John L. Parker,et al.  Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial , 2019, The Lancet Neurology.

[4]  E. Buchser,et al.  Systematic review and meta-analysis of placebo/sham controlled randomised trials of spinal cord stimulation for neuropathic pain. , 2019, Pain.

[5]  Martin Underwood,et al.  Prevention and treatment of low back pain: evidence, challenges, and promising directions , 2018, The Lancet.

[6]  Linda A. Lindsay,et al.  Spinal Cord Stimulator Implant , 2017 .

[7]  E. Buchser,et al.  Complications of Spinal Cord Stimulation and Peripheral Nerve Stimulation Techniques: A Review of the Literature. , 2015, Pain medicine.

[8]  Thomas L Yearwood,et al.  Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial , 2015, Anesthesiology.

[9]  A. Mailis,et al.  Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. , 2012, Pain research & management.

[10]  J. O’Callaghan,et al.  Recommendations for patient selection in spinal cord stimulation , 2011, Journal of Clinical Neuroscience.

[11]  P. House The Effects of Spinal Cord Stimulation in Neuropathic Pain Are Sustained: A 24-Month Follow-up of the Prospective Randomized Controlled Multicenter Trial of the Effectiveness of Spinal Cord Stimulation , 2009 .

[12]  Krishna Kumar,et al.  Spinal epidural abscess , 2005, Neurocritical care.

[13]  R. Pawl Spinal cord stimulation. , 2020, The Clinical journal of pain.

[14]  W. Inman,et al.  Under-reporting of adverse drug reactions. , 1985, British medical journal.